Janssen obtains FDA approval for Darzalex (multiple myeloma)

Janssen, part of Johnson & Johnson group, has announced it has obtained the FDA approval for Darzalex in combination with Takeda’s Velcade and prednisone as a first-line therapy against multiple myeloma.